Skip to main content

Or 34,00 After 66% tax deduction

I make a monthly donation I make an IFI donation
Imagerie cérébrale Corti Corvol Parkinson

Parkinson's disease

Causes, biological mechanisms, symptoms, diagnosis and treatment

Last update: 04/10/2024 Reading time: 1min

Parkinson's disease is the most common neurodegenerative disease after Alzheimer's and the first cause of parkinsonian syndrome.

Parkinson's disease is the 2nd most common neurodegenerative disease after Alzheimer's disease. It currently affects 270,000 people in France, with the number of new cases rising steadily each year as the population ages.

The most important risk factor for developing Parkinson's disease is age, with a prevalence of 0.04% in people aged between 40 and 49, rising to 2% in the over-80s.

Men are more affected than women, with a ratio of 2 men to 1 woman after the age of 40.

Parkinson's disease is characterised by degeneration of the dopaminergic neurons in the substantia nigra of the brain, located in a particular region of the brain stem and composed mainly of dopamine neurons. Other regions may also be affected, resulting in ‘non-motor’ disorders such as sleep disorders, blood pressure disorders or, later on, walking disorders, each of which corresponds to different neuronal circuits.

From a symptomatic point of view, the best-known clinical signs of the disease are resting tremors, but the most frequent and characteristic are slowness of movement or akinesia and muscular rigidity.

Most treatments are aimed at improving symptoms and slowing the progression of the disease.

02.04.2024 Understand in 2 minutes : Parkinson's disease
Causes

The causes of Parkinson's disease

5% of cases of Parkinson's disease are familial, i.e. inherited through mutation of a dominant or recessive gene. To date, 13 genes have been identified as causative in this disease.

Other cases are sporadic, in which the disease develops following exposure to an environmental factor in genetically predisposed individuals. Parkinson's disease, like many neurological diseases, is said to be multifactorial. Numerous environmental factors and genetic predisposition factors conferring a higher risk of developing the disease have been identified in recent years.

Find out more about the Brain Institute's research on the page dedicated to the causes of Parkinson's disease.

Biological mechanisms

The biological mechanisms of Parkinson's disease

The main molecular player in Parkinson's disease is a protein expressed in neurons called α-synuclein. During the course of the disease, this protein pathologically aggregates to form clusters known as Lewy bodies. This phenomenon occurs mainly in the dopaminergic neurons of the substantia nigra, a region located in the brain stem, but also appears in other areas of the brain during Parkinson's disease. The death of neurons linked to a-synuclein aggregates leads to a deficit in the production of neurotransmitters, the molecules that enable communication between neurons, triggering the onset of symptoms.

Find out more about the Institut du Cerveau's research on the page dedicated to the biological mechanisms of Parkinson's disease.

 Symptoms, diagnosis and course

Symptoms, diagnosis and course of Parkinson's disease

The symptoms observed in Parkinson's patients are caused by damage to the substantia nigra and striatum, followed by other brain regions.

The 1st symptoms that lead to a diagnosis of Parkinson's disease are akinesia (slowness of movement), muscular hypertonia (stiffness of the muscles) and tremors at rest that disappear during a voluntary movement. These symptoms together constitute the Parkinson's syndrome.

The diagnosis of Parkinson's disease is based on the demonstration of a pure, asymmetric parkinsonian syndrome that is sensitive to dopaminergic treatment.

Treatments

Treatments for Parkinson's disease

The aim of the treatments prescribed to Parkinson's patients is to compensate for the dopamine deficit inherent in neuronal death. There are two types of treatment:

  • L-DOPA, a dopamine precursor molecule capable of crossing the blood-brain barrier, which is converted into dopamine in the brain.
  • Dopaminergic agonists, molecules with the same effect as dopamine.
    These two treatments for Parkinson's act in the same way and aim to re-establish the faulty transmission between neurons. Unfortunately, they have no effect on the cause or progression of the disease.

Deep brain stimulation is also a frequent therapy used to treat the symptoms of the disease.

Other non-medicinal approaches such as regular physical activity and intellectual activities are beneficial for Parkinson's disease disorders.

Our news on the subject

Réprésentation du danse lors du petit déjeuner
2023 Art-Science Breakfast: restoring movement for Parkinson’s patients
In partnership with the Paris+ par Art Basel contemporary art fair, the 12th edition of the Art-Science Breakfast took place on October 18, 2023 at Café de l’Homme. Thanks to support from the NRJ Foundation at Institut de France and the incredible ...
10.20.2023 Support
image
How to discern impulsivity from alteration of anticipation?
In everyday life, we all need to anticipate our actions. On the road, for example, we need to start or cross when the light turns green. While the light is red, our brain prepares to act as quickly as possible as soon as the color changes because we ...
10.13.2022 Research, science & health
image
Genetics of early-onset parkinsonism with intellectual disability
A research team from the Paris Brain Institute (Inserm/CNRS/Sorbonne University/AP-HP) just identified mutations in familial cases with early-onset Parkinsonism and intellectual disability. Genetic studies on two affected siblings pairs highlighted ...
09.29.2022 Research, science & health
Un chercheur
World Parkinson's Day 2022: where does research stand?
On the occasion of World Parkinson's Day, which will be held on 11 April 2022, the Paris Brain Institute takes stock of the latest advances in research and the challenges that remain in the fight against the second most common neurodegenerative ...
04.11.2022 Research, science & health
image
Artificial Intelligence-based MRI biomarker of Isolated REM Sleep Behavior Disorder and Parkinson's disease
Rahul Gaurav, a research Engineer in the MOV’IT team led by Pr. Stéphane Lehéricy and Pr. Marie Vidailhet, at the Paris Brain Institute, developed an artificial intelligence framework to investigate fully automatic neurodegeneration in the substantia ...
02.18.2022 Research, science & health
sommeil
Sleepwalking and behavioral disorders in rem sleep: shared characteristics?
Restlessness in sleep is common, however it may be a symptom of two illnesses that seem to be complete opposites: sleepwalking and behavioral disorders in REM sleep. The first affects a younger population and takes place during deep sleep, whereas ...
07.26.2017 Research, science & health
See all our news